The T-cell leukemia 1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement in the majority of cases of T-cell prolymphocytic leukemia (T-PLL). In vitro, TCL1 can modulate the activity of the serine-threonine kinase AKT, a downstream effector of T-cell receptor (TCR) signaling. In a series of 86 T-PLL tumors, we show that expression of TCR, and levels of TCL1 and activated AKT are adverse prognostic markers. High-level TCL1 in TCR-expressing T-PLL is associated with higher presenting white blood cell counts, faster tumor cell doubling and enhanced in vitro growth response to TCR engagement. In primary tumors and TCL1-transfected T-cell lines, TCR engagement leads to rapid recruitment of TCL1
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Background
T-cell leukemia 1 (TCL1) was identified as the oncogene insertionally activated by the T-cell receptor enhancer through inv(14)(q11;q32.1) or t(14;14) (q11;q32.1) in Tcell prolymphocytic leukemia (T-PLL).
1-3 TCL1 activation is seen in 70-80% of T-PLL but not in other T-cell tumors types. [4] [5] [6] [7] [8] [9] Most cases of T-PLL are highly aggressive with optimal therapy not yet established. 6, [10] [11] [12] Although there are few large series, several immunophenotypic tumor subsets with differing outcomes likely exist. 6, 8, [13] [14] [15] [16] [17] TCL1, which is not expressed in non-neoplastic mature T cells, is one member of a family of small beta-barrel proteins found predominantly in the cytoplasm whose mechanism of action remains unresolved. Rare cases of T-PLL overexpress another TCL1 homolog, MTCP1, through a X;14 translocation.
18,19
When overexpressed in non-lymphoid cell line models, TCL1 has been shown to bind to the pleckstrin homology (PH) domain of AKT and to regulate its activity.
20-22
This finding and subsequent structural data have suggested that TCL1 homodimers could act by promoting AKT dimerization, thus facilitating AKT transphosphorylation. 23, 24 Given the rarity of this tumor type, the regulation of TCL1
and AKT in primary T-PLL tumor cells has not been previously explored.
Here, we compare the clinical and immunophenotypic patterns of T-PLL and identify T-cell receptor (TCR) expression, AKT activation and TCL1 levels as correlates of poor outcome. We show that TCR stimulation leads to rapid recruitment of TCL1,
AKT and tyrosine kinases to membrane-associated activation complexes and that 
Materials and Methods
Patient samples and hematologic parameters
This study included all patients with T-PLL that had available pathologic material and centrifugation of peripheral blood (PB). Trypan blue staining was used to assess viability.
Primary tumor cultures and cell lines
T-PLL tumor cells were isolated from blood samples comprising ≥ 90% of all white blood cells (WBC). Primary tumors from 26 cases as well as established cell lines were grown in 15% fetal calf serum in RPMI culture media with 1% penicillin-streptomycin (Gibco For personal use only. on April 18, 2017. by guest www.bloodjournal.org From Laboratories, Grand Island, NY) and, in the case of cell lines, harvested in mid-logarithmic phase. Stimulatory reagents included interleukin-2 (IL2) at 25ng/ml (PeproTech, Rocky Hill, NJ), phorbol-12-myristate-13-acetate (PMA) at 50-100ng/ml (Sigma-Aldrich, St. Louis, MO), ionomycin and concanavalin A (ConA), at 25-50µg/ml and 1µM, respectively (Calbiochem, La Jolla, CA). For TCR crosslinking, 50µg/ml of anti-CD3 (OKT3) and 25µg/ml anti-CD28 (CD28.2, both eBioscience, San Diego, CA), coated onto culture plates before addition of sample, were used. Working concentrations for the PI3-kinase (PI3K) inhibitor LY294002 (Cell Signaling Technology, Inc., Beverly, MA) were 10-20µM, for the integrin linked kinase (ILK) inhibitor QLT0267 (QLT Inc., Vancouver, British Columbia, Canada) 10-40µM, and for the competitive AKT kinase inhibitor A443654 (Abbot Laboratories, Abbot Park, IL) they were 0.5-5µM. The TCL1-negative (-) cell lines used included immature (Jurkat, CCRF-HSB2, CCRF-CEM, Molt-4) as well as mature (HH, Hut78, SKW3) T-cell tumor lines (ATCC, Manassas, VA) and TCL1-transfectants of all of these. A functional TCR pathway following CD3 engagement was present in Jurkat (derived from precursor T-lymphoblastic leukemia), HH and Hut78 (both derived from CD4+ Sézary leukemias).
Establishment of TCL1-expressing leukemic cell lines
A retroviral TCL1-construct containing human TCL1 cDNA in a murine stem cell virus (MSCV) vector as described earlier 4 was used to create stably-transfected T-cell lines. The
Phoenix packaging cell line 293T (courtesy Dr. G. Nolan, Stanford) was transfected with isolated vector plasmid DNA by CaCl 2 coprecipitation and purified for cells with the integrated construct by 10µg/ml puromycin (A.G. Scientific Inc., San Diego, CA). After preFor personal use only. on April 18, 2017. by guest www.bloodjournal.org From incubation with 5µg/ml polybrene, target cells were infected with the viral supernatants containing either MSCV-GFP-ires-puro or MSCV-TCL1-ires-puro 4 in an optimized centrifugation protocol and selected for puromycin-resistance. Efficiency of T-cell line transfection, as evaluated by the GFP-containing control, ranged from 40-90% preselection, with stably TCL1-transfected lines obtained post-selection from all cell lines.
siRNA transfection experiments
A TCL1-expressing subclone of the T-cell leukemia line HH line was transfected with 15µg of TCL1 (SMARTpool, Dharmacon, Lafayette, CO) or nonsense scrambled siRNA duplexes (Invitrogen, Carlsbad, CA) using nucleofection (Amaxa, Germany, Solution V, program O16). The cultures, all with a cell viability of more than 80%, were studied at 72 hours after transfection for effects of TCR engagement. Functional read-outs included TCL1 and phosphoprotein levels, AKT kinase activity and cell proliferation.
MTT proliferation assays
For estimation of T-cell proliferation and cytotoxicity, we assessed metabolic activity and viability in the colorimetric MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide]) assay (CellTiter96 ® , Promega, Madison, WI) as described earlier. 28 Experiments were repeated at least twice.
Production of a monoclonal TCL1 antibody
A monoclonal antibody (designated 1-21) was produced against a specific 14 amino acid peptide epitope that maps to the outer α-loop region of TCL1, by standard immunization procedures and fusion of BALB/c mice spleen cells with the myeloma line NS1 followed by Spring Harbor Laboratory, NY). Western blots using this antibody detected a strong single 13.5kDa band in cells transfected with a TCL1-expressing construct (above). The specificity of the antibody was verified by mass spectrometry-based peptide sequencing of the band. Briefly, proteins immunoprecipitated with the 1-21 antibody were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), visualized by silver staining, excised, digested overnight with modified trypsin (Promega), and analyzed by tandem mass spectrometry (LC-MS/MS) using an electrospray ionization ion-trap mass spectrometer (LTQ, Thermo Electron, San Jose, CA). Mass spectra were searched against the NCBI non-redundant human database, using Mascot. Search results indicated antibody specificity for TCL1 based on three peptide sequences. Sequences derived from the related proteins TCL1B (TML1) and MTCP1 were not detected.
Western blot analysis
Whole cell lysates or fractionated nuclear/cytoplasmic extracts (NE-PER TM , Pierce Biotechnology, Rockford, IL) were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and proteins detected using the ECL system (Amersham Biosciences). Lysis buffers are described elsewhere. experiments. Signal intensity levels were compared based on densitometry analysis using the ImageJ software (National Institutes of Health, Bethesda, MD). TCL1 and pAKT-S473 levels on Western blot were graded as absent (0), low (1) and high (2) .
AKT kinase activity assays
In addition to pAKT-substrate RXRXXS/T-motif Western blots (above), in vitro kinase (NL213, 1:500, Upstate, Lake Placid, NY). Antigen retrieval was done as published. 28, 29 Immunohistochemical results were scored semiquantitatively based on the same 3-tier scoring system (0-absent, 1-dim, 2-strong staining). Confirmatory TCL1 assessment, with concordant results to immunostaining except in 2 cases, was done by Western blot or flow cytometry with a standard permeabilization protocol and AlexaF488-labeled TCL1 antibody (1-21). The specificity of each phosphoprotein antisera was confirmed by detection of appropriate-sized bands on Western blots using 30 T-PLL lysates.
Confocal microscopy
Preparation and fixation of cytospins from single cell suspensions as well as staining procedures were done as described. 28 The primary antibodies detected TCL1 (clone 1-21, Table 1 1D ) and shorter pre-treatment LDT (p=0.03, Fig.1E ).
RESULTS
High-level expression of TCL1 is associated with the hyperproliferative subset T-PLL
Functional response to TCR engagement in T-PLL is associated with high TCL1 expression
To identify correlates of increased proliferation in TCL1+ T-PLL, we performed immunohistochemical and flow cytometric profiling of components of the TCR pathway such as coreceptors, activation markers, kinases and phosphatases. We identified respective subsets of T-PLL in relationship to T-cell development and TCR signaling activity (summarized in Table 1 and CD69 were generally less significant than for sTCR, pAKT and TCL1 (Table 1) . In a multivariate analysis of tumor-associated phenotypic markers, high TCL1 expression, sTCR and pAKT-S473 all retained their significance as prognostic factors, even after inclusion of age into the model (Table 2 , left). TCR expression was, in addition to presenting WBC count and pre-treatment LDT, also an independent predictor of poor outcome in a further regression analysis that included clinical parameters ( Table 2 , right).
Freshly isolated T-PLL tumor cells showed responsiveness to TCR engagement and other growth stimuli in relation to TCL1 expression. Among 19 primary T-PLL tumors, in vitro growth stimulation in response to anti-CD3/CD28 crosslinking was restricted to the presence of sTCR expression, whereas nearly all cases showed growth stimulation in response to ConA/IL2 and PMA/ionomycin (Fig.2C) . Among the subset of sTCR expressing T-PLL, the proliferative response to TCR engagement in cases that were strongly positive for TCL1 surpassed that of TCL1-low/negative tumors (Fig.2D ).
Stimulated T-PLL growth in culture was associated with increased levels of activated pAKT-S473 and mitogen-activated protein kinase (p-ERK1/2, p42/44) as detected by
Western blot in the 26 cases studied. However, the kinetics of maximal phospho-activation of AKT and ERK1/2 revealed a relationship to tumor TCL1 levels. In T-PLL that highly expressed TCL1, AKT activation was seen as early at 5-15 minutes post-stimulation (Fig.2E, left panel) , whereas in tumors with lower TCL1 levels this often occurred at much later time points (Fig.2E, right panel) .
For
TCR engagement in T-PLL leads to rapid recruitment of TCL1 and AKT to the T-cell receptor complex
Prior to a growth stimulus, TCL1 and AKT in freshly isolated T-PLL tumors showed predominantly cytoplasmic distribution as determined by cell fractionation and were not colocalized by confocal microscopy (Fig.3A top, and not shown) . Upon TCR engagement, there was rapid recruitment of TCL1 and AKT to perimembraneous sites within 5 minutes of exposure. By 30 minutes of stimulation, TCL1 and activated pAKT-S473 were colocalized to discrete membrane foci also containing TCR-associated kinases such as LCK (Fig.3B) . The appearance of these complexes was consistent with the supramolecular activation clusters associated with the immunological synapse in non-neoplastic T cells following TCR engagement. 31 The pattern of TCL1-AKT colocalization following initial membrane recruitment was highly dependent on the type and duration of the activation stimuli. With PMA/ionomycin or ConA/IL2, TCL1 and AKT showed recruitment to perimembraneous locations but not to TCR foci (Fig.3A , bottom panels and not shown). TCL1-AKT activation complexes were also reversible, with loss of perimembraneous TCL1-AKT colocalization within 2 hours after washout of the activation stimuli in the majority of cells (not shown). Continuous ConA/IL2 or TCR engagement for up to 4 days led to the appearance of nuclear TCL1 and AKT-containing foci and correlated with the degree of proliferation observed (not shown).
Inhibitors of AKT activation block TCL1-AKT complex formation and reduce growth of T-PLL
Maximal AKT activation in T-PLL cultures, as assessed by pAKT-S473 Western blot, was seen at 15-30 minutes following TCR engagement (Fig.4A, left) , at a time that coincided with the first appearance of the discrete TCR-associated foci noted by confocal microscopy. Using an immobilized AKT antibody for immunoprecipitation of activated AKT complexes in 6 T-PLL samples, we noted that maximal association between TCL1 and AKT also correlated with peak AKT activation (Fig.4A , lower left panels). Maximal phosphorylation of the AKT target peptide GSK3α/β by immunoprecipitated AKT also correlated with the timing of maximal TCR-stimulated TCL1-AKT complexes.
We assessed the effects of inhibitors that differentially affect AKT activation in 6 T-PLL cultures, including the PI3K inhibitor LY294002, the ILK inhibitor QLT0267, and the competitive AKT inhibitor A443654. All 3 drugs abolished the effects of TCR crosslinking on activation of AKT, and led to reductions in coimmunoprecipitated TCL1 along with decreased GSK substrate and pan-RXRXXS/T target motif phosphorylation (Fig.4A, and not shown). A443654 treatment led to increased baseline pAKT-S473 but decreased baseline levels of coimmunoprecipitated TCL1 consistent with inhibition of TCL1-pAKTsubstrate complex formation. In contrast, incubation of the in vitro kinase reaction directly with A443654 while it also suppressed GSK3 and RXRXXS/T-motif phosphorylation did not affect the amount of detected TCL1 (not shown).
By confocal microscopy, we observed a delayed and reduced colocalization of AKT and TCL1 after LY294002 inhibition (not shown). In A443654-treated T-PLL cells, we noted striking accumulations of TCL1 and AKT in the cytoplasm, especially following TCR engagement, but virtual absence of AKT-TCL1 membrane-associated complexes. All three inhibitors directed against AKT activation also reduced cell proliferation in T-PLL cultures (Fig.4B) . Among them, A443654 induced the most marked apoptosis, as evidenced by cell blebbing and nuclear fragmentation. This apoptotic effect was partially overcome by CD3/CD28-crosslinking.
Introduction of TCL1 into T-cell leukemia augments basal and stimulated AKT activity and renders tumor cells more resistant to inhibition of AKT
Cell lines stably expressing full-length TCL1 protein were created from seven T-cell leukemia lines lacking TCL1. In comparison to their TCL1-parent cell lines, these 7 TCL1-transfected subclones had variably but overall slightly higher levels of baseline activated pAKT (Fig. 5A ) and a 1.2-1.8-fold increased proliferative rate in the sTCR-expressing lines (HH, Hut78 and Jurkat) but not in sTCR-lines (Molt4, CEM, HSB2, SKW3; not shown). In the TCL1-expressing subclones, activated AKT levels were also higher after TCR stimulation and the lines were more resistant to apoptosis following treatment with the inhibitor A443654 (Fig. 5A, not shown) . Immunoprecipitated AKT complexes also showed higher kinase activity on exogenous GSK substrate at baseline and following TCR engagement in the TCR+ TCL1-expressing lines (Fig. 5A, lower panel) . Overall T-PLL cases that were negative or low for TCL1, including some carrying a chromosome 14q32 rearrangement, showed lower pre-treatment WBC counts and LDT.
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The association of TCL1 level with aggressiveness and adverse outcome in T-PLL was strongest when only sTCR+ cases were studied (p=0.018) as compared to inclusion of all tumors, further indicative of TCR-TCL1 cooperativity. In T-PLL, we propose that TCL1 augments TCR pathway responsiveness in the early stages of development of T-PLL, and is sometimes downmodulated with subsequent tumor progression when its growth promoting effects are less critical for tumor survival. The strong association of TCR pathway responsiveness with high TCL1, in our series, extends to some coreceptors, protein kinases and phosphatases that are downstream of TCR activation (see Table 1 ).
This apparent TCR and TCL1 cooperativity may also be related to the previously identified association of outcome in T-PLL with CD45RA versus CD45RO expression or to coexpression of the CD4 and CD8 coreceptors 8, 13, 38 The ability of TCL1 to modulate AKT signaling through a variety of stimuli has also important implications for its role in lymphocyte biology.
39 Dysregulated TCL1 as a result of specific chromosomal aberrations has not been shown in other lymphatic tumors. 28, 29, 40 In non-neoplastic lymphoid cells, TCL1 is expressed in a small subset of thymocytes, in plasmacytoid dendritic cells and in B cells up to the germinal center (GC) stage of maturation. 5, 30, 34, [41] [42] [43] [44] [45] [46] In non-neoplastic T cells, TCL1 is expressed only at the earliest stages of thymocyte development before the TCR signaling pathway is assembled. 4, 41 Similarly, in non-neoplastic B cells, TCL1 expression is lost at the GC stage of maturation when B-cell receptor (BCR) signaling through appropriately presented antigen occurs. 29, 30, [41] [42] [43] [44] [45] [46] [47] This developmentally regulated silencing of TCL1 at the onset of antigen receptor signaling suggests that TCL1 may substitute for the effects of TCR and BCR engagement on AKT activation and lower the threshold for AKT signaling by other growth
stimuli (e.g. cytokines). The phenotype of TCL1-deficient mice, which is characterized by mildly impaired B-cell and T-cell response to growth and differentiation stimuli, also supports this model. 
